Although not directly tested in this study, we predict that HAT1 expression levels in samples from patients with progressed disease states can be used as an indicator of IGF1R and ERK1/2 inhibitor sensitivity, due to the activation of the IGF1R and MAPK pathways in melanoma cells expressing low levels of HAT1. Although, we have not directly tested the BRAFi + MEKi combination in our cell culture experiments. This evidence concerns the gene MAPK3 and melanoma.